Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

Thomas Bachelot ,A-C Hardy Bessard,Pietrina Cottu ,J.p Jacquin ,Julien Grenier ,Sylvie Giacchetti ,Laurence Venat-Bouvet ,Étienne Brain ,J-L Canon ,Marc Debled ,Francesco Del Piano ,Judith Bliss ,Mario Campone ,Florence Dalenc ,Djelila Allouache ,Sylvie Chabaud ,Murray Brunt ,David Cameron ,Jérôme Lemonnier ,Fabrice André

doi:10.1016/j.annonc.2021.02.003

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

Thomas Bachelot , A-C Hardy Bessard + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.02.003

Copy DOI

Journal: Annals of Oncology	Publication Date: Feb 19, 2021
Citations: 10	License type: elsevier-specific: oa user license

Affiliation: Centre Léon Bérard, Institute Curie, Institute Cancer De La Loire Lucien Neuwirth, Institut Sainte Catherine, Hôpital Saint-Louis, Hôpital Dupuytren, Ethypharm (France), Grand Charleroi Hospital, Institut Bergonié, Institute of Cancer Research, Institut de Cancérologie de l'Ouest, Institut Claudius Regaud, Centre François Baclesse, Royal Stoke University Hospital, Western General Hospital, UniCancer Group, Institut Gustave Roussy

#Everolimus In Combination #Early Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Everolimus (EVE) in combination with hormone therapy (HT) has been shown to improve progression free survival for advanced HR+/HER2- breast cancer (BC). The double blind randomized UNIRAD trial aimed to investigate the benefit of adjuvant EVE in combination with standard adjuvant HT versus HT alone for women with high-risk HR+/HER2- early BC.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.